The U.S. Food and Drug Administration (FDA) approved a generic version of Dapagliflozin And Saxagliptin (ANDA 211533) on April 6, 2026. This approval allows for a new therapeutic option for patients, with MSN listed as the sponsor.
What this means
The approval of a generic version of Dapagliflozin And Saxagliptin is a significant development, typically leading to increased patient access and potentially more affordable treatment options. Generic drugs are required to meet the same rigorous standards as their brand-name counterparts, ensuring comparable quality, strength, purity, and stability.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA) database. The approval for ANDA 211533, concerning Dapagliflozin And Saxagliptin, was recorded on April 6, 2026, on accessdata.fda.gov.